Rose became acquainted with Patient Worthy after her husband was diagnosed with Acute Myeloid Leukemia (AML) six years ago. During this period of partial remission, Rose researched investigational drugs to be prepared in the event of a relapse. Her husband died February 12, 2021 with a rare and unexplained occurrence of liver cancer possibly unrelated to AML.
source: shutterstock.com
One year ago, Jenny Decker age 40 began her journey around the world sailing 3,200 miles to her first stop in Fiji. She reported to Practical Boat Owner that she…
Continue Reading
Jenny Decker May Have Charcot-Marie-Tooth Disease, but She is Sailing Around the Globe
source: pixabay.com
This week Neurocrine Biosciences announced the results of its KINECT®-4 Phase 3 study of INGREZZA® capsules. Results of the trial were published in the Journal of Clinical Psychopharmacology. A long-term…
Continue Reading
Tardive Dyskinesia: Phase 3 Study Results Indicate Improvement with Use of INGREZZA®
shutterstock.com
Cartesian Therapeutics, Inc., a biotechnology company, recently announced that the FDA has awarded the Regenerative Medicine Advanced Therapy (RMAT) designation to its lead product, Descartes-08, to treat myasthenia gravis (MG).…
Continue Reading
Cartesian Therapeutics Earns Regenerative Medicine Advanced Therapy Designation for Myasthenia Gravis
source: shutterstock.com
Occasionally the acronym NEGU may appear in a social media post. It has been established as a rallying cry and support for people with cancer or other debilitating diseases. It…
Continue Reading
Karen Overpowered Dystonia and Passes the Freedom, Like the Olympic Flame, to her Readers
BioSpace recently published a press release discussing the interim results highlighting a Coya Therapeutics’ study. The study evaluates the safety, tolerability, and biological activity of LD IL-2 in 38 patients…
Continue Reading
Encouraging Results from a Phase 2 Study of IL-2 to Treat Alzheimer’s Patients
source: shutterstock.com
Jianmin Fang, M.D. the CEO of the biotechnology company RemeGen, recently announced in PRNewswire that the company is continuing its significant progress in its research of Telitacicept (RC18) to treat…
Continue Reading
Enrollment Completed in Clinical Trials for Primary Sjögren’s Syndrome and IgA Nephropathy
source: shutterstock.com
A major illness can rob some people of their strength and courage, but in other cases it motivates people to get help and, if possible, to help others. 20 years…
Continue Reading
She Has Cervical Dystonia but Will Wing Walk on a Biplane to Raise Awareness
source: pixabay.com
People who have bipolar depression face a 50% lifetime risk of attempting suicide and a 20% risk of death from suicide. Over seven million people in the U.S. are struggling…
Continue Reading
Suicidal Bipolar Depression: Clinical Trial Results of NRX-101 Found Superior Safety and Similar Efficacy Compared to Lurasidone
source: shutterstock.com
In a clinical trial conducted by Dr. Talal and his colleagues, the team compared hepatitis C response rates for 602 patients with opioid use disorders. The trials took place…
Continue Reading
Telemedicine Programs Improve Cure Rates for Hepatitis C vs. Specialist Referral
source: shutterstock.com
As reported in Biopharma Dive, the FDA’s decision to strengthen its authority involving laboratory developed tests (LDTs) has drawn considerable objections from various healthcare groups. However, the Agency has held…
Continue Reading
New FDA Regulation on Laboratory Developed Tests Draws Objections from Healthcare Groups
You may not have heard of spinocerebellar ataxia 4 (SCA4). It is rare and it is a devastating movement disease. SCA4 generally begins when a person is 40 or 50,…
Continue Reading
ICYMI: After a 25 Year Search, a Doctor Discovers the Cause of Spinocerebellar Ataxia 4
source: shutterstock.com
The ALS space looked promising in 2022 after Relyvrio’s approval and a green light for Oalsody in 2023. Then progress stalled a bit in 2024 as a result of Relyvrio…
Continue Reading
Amyotrophic Lateral Sclerosis (ALS): Where Are We Now and Where Are We Going?
Patients Aged 80 to 90 Respond to Standard-of-Care AML Treatment | Inside Precision Medicine
Continue Reading
WHATNEXT: Patients Aged 80 to 90 Respond to Standard-of-Care AML Treatment
source: shutterstock.com
Angelman syndrome begins at birth and although symptoms vary, most children exhibit common developmental delays such as: • Infants showing an inability to support their head • Unable to pull…
Continue Reading
A Therapy for Angelman Syndrome Shows Promise, but Adverse Effects Leave Questions
source: shutterstock.com
Unexpected but positive results from a late-stage clinical trial were announced by Cerevel Therapeutics and reported in BioPharma Dive last week much to the surprise of AbbVie, the company that…
Continue Reading
An Investigational Drug to Treat Parkinson’s Produced Surprising Results
source: pixabay.com
On one side of the equation pharmaceutical companies maintain that if drug prices are restricted it will have a negative impact on innovation. Health economists, on the other hand, maintain…
Continue Reading
His Son’s Diagnosis Inspired a New Biotech Company
An American triathlete, Jon Blais, received a diagnosis of amyotrophic lateral sclerosis (ALS) in 2005 when he was 33 years old. The disease is incurable. Jon was told he had…
Continue Reading
EU Researchers Begin Working on an ALS Treatment and Vaccine
source: shutterstock.com
Exa-cel Gene-Edited Therapy Vertex Pharmaceutical recently announced that Health Canada has accepted its New Drug Submission and granted Priority Review for Exa-cel, a gene-edited cell therapy, for the treatment of…
Continue Reading
Health Canada Accepts Priority Review of New Drug Submission for Exa-cel for Sickle Cell Disease and Beta Thalassemia
source: shutterstock.com
A recent lab study led to an improved understanding of asthma and its mechanisms of action. The co-senior author of the study, Professor Chris Brightling and his colleagues at the…
Continue Reading
Study of Bronchial Asthma Reveals Cause of Cell Damage
source: shutterstock.com
Patients with moderate to severe Crohn’s disease have found quick relief from abdominal pain and stool frequency during the first week of induction therapy according to data analysis published in…
Continue Reading
Clinical Trial: Rinvoq 45 mg Brings ‘Rapid Resolution’ of Crohn’s Disease Symptoms
source: pixabay.com
Approximately 540,000 individuals in the United States have been diagnosed with autosomal dominant polycystic kidney disease (ADPKD). The disease causes persistent and rapidly accumulating cysts to grow in the patient’s…
Continue Reading
Investigational Treatment for ADPKD Earns FDA’s Orphan Drug Designation
source: shutterstock.com
These efforts led to collaboration by the International Brain pH Project that involves 131 scientists in 105 labs from seven countries. The scientists have identified changes in lactate levels…
Continue Reading
Scientists have Discovered a Connection Between Metabolic Problems in the Brain and Neurological Disorders
source: pixabay.com
What is primary immunodeficiency? The Mayo Clinic offers this definition: "PI weakens the immune system and as a result infections or other health problems may occur more often. People with…
Continue Reading
World Primary Immunodeficiency (PI) Week is April 22-29
source: shutterstock.com
Previously, Patient Worthy reported on research focused on the use of a pig kidney in a transplant operation involving a human patient. Richard (Rick) Slayman was released from the hospital…
Continue Reading
Man with Pig Kidney Leaves Hospital, with All Signs Pointing to Success
Xstim, Inc. Receives FDA Approval for Xstim™ Spine Fusion Stimulator. (prnewswire.com)
Continue Reading
Xstim, Inc. Receives FDA Approval for Xstim™ Spine Fusion Stimulator